METHODS AND NUCLEIC ACIDS FOR THE ANALYSIS OF GENE EXPRESSION ASSOCIATED WITH THE PROGNOSIS OF PROSTATE CELL PROLIFERATIVE DISORDERS

• US 20090197250A1
• Filed: 12/02/2005
• Published: 08/06/2009
• Est. Priority Date: 12/02/2004
• Status: Abandoned Application

• Current Assignee: Epigenomics AG
• Original Assignee: Epigenomics AG
• Inventors: Thomas, Jeffrey G., Skillman, Thomas L., Sledziewski, Andrew Z., Model, Fabian, Distler, Juergen, Song, Xiaoling, Cottrell, Susan, Weiss, Gunter, Haefliger, Carolina
• Application Number:
  US11/720,744
• Publication Number:
  US 20090197250A1
• Time in Patent Office: Days
• US Class Current: 435/6.14
• CPC Class Codes: C12Q 1/6886 for cancer immunoassay for cancer G01N33/574
• CPC Class Codes: C12Q 2600/106 Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
• CPC Class Codes: C12Q 2600/118 Prognosis of disease development
• CPC Class Codes: C12Q 2600/154 Methylation markers
• CPC Class Codes: C12Q 2600/158 Expression markers
• CPC Class Codes: C12Q 2600/16 Primer sets for multiplex assays
• CPC Class Codes: G01N 2800/60 Complex ways of combining multiple protein biomarkers for diagnosis
• CPC Class Codes: G01N 33/57434 of prostate

Abstract

Particular aspects provide novel methods and compositions (e.g., nucleic acids, kits, etc.) having substantial utility for providing a prognosis of prostate cell proliferative disorders. In particular aspects, this is achieved by the analysis of the expression status of a panel of genes, or subsets thereof.

Claims

1. A method for providing a prognosis of a subject with a prostate cell proliferative disorder comprising:

obtaining a biological sample from a subject;

determining the expression status of at least one gene or genomic sequence selected from the group consisting PITX2, HIST2H2BF, SEQ ID NO;

63, GPR7, SEQ ID NO;

35 and FOXL2 in said sample; and

determining therefrom the prognosis of said subject whereby expression is indicative of prognosis of a prostate cell proliferative disorder.

2. The method of claim 1, wherein determining the prognosis comprises consideration of at least one further prognostic variable.

3. The method of claim 2, wherein said at least one further prognostic variable is selected from the group consisting of nomogram, PSA level and Gleason score.

4. The method of claim 1, wherein said prognosis is determined in terms of at least one of the group consisting of overall patient survival, disease- or relapse-free survival, tumor-related complications and rate of progression of tumour.

5. The method of claim 1, further comprising:

determining, based on the prognosis, a suitable treatment for said subject.

6. The method of claim 1, wherein said prostate cell proliferative disorder is a prostate carcinoma or prostate neoplasm.

7. The method of claim 1, wherein the at least one gene is PITX2.

8. The method of claim 1, wherein said genomic sequence is SEQ ID NO:

35.

9. The method of claim 1, wherein said genomic sequence is SEQ ID NO:

63.

10. The method of claim 6, wherein said disorder is T2 prostate carcinoma.

11. The method of claim 6, wherein said disorder is prostate carcinoma with a Gleason score of eight or higher.

12. The method of claim 7, wherein said subject has a poor prognosis based on nomogram score.

13. The method of claim 1, wherein the sample is selected from the group consisting of cells or cell lines, histological slides, biopsies, paraffin-embedded tissue, bodily fluids, ejaculate, urine, blood, and combinations thereof.

14. The method of claim 1, wherein the expression is determined by measuring the level of at least one of mRNA, cDNA or polypeptide.

15. The method of claim 14, wherein the expression is determined by use of at least one technique selected from the group consisting of Northern blot analysis, reverse transcriptase PCR, real-time PCR, RNAse protection, and microarray analysis.

16. The method of claim 1, wherein said expression is determined by determining the level of methylation or methylation status of one or more CpG positions within said at least one gene or genomic sequence.

17. The method of claim 16, comprising contacting genomic DNA isolated from a biological sample obtained from the subject, with at least one reagent, or series of reagents that distinguishes between methylated and non-methylated CpG dinucleotides within at least one target region of the genomic DNA, wherein the target region comprises, or hybridizes under stringent conditions to a sequence of at least 16 contiguous nucleotides of at least one gene or sequence selected from the group consisting of PITX2, SEQ ID NO:

63, GPR7 and SEQ ID NO;

35, wherein said contiguous nucleotides comprise at least one CpG dinucleotide sequence, and whereby providing a prognosis of prostate cell proliferative disorders is, at least in part, afforded.

18. The method of claim 17, comprising:

isolating genomic DNA from a biological sample taken from said subject;

treating the genomic DNA, or a fragment thereof, with one or more reagents to convert 5-position unmethylated cytosine bases to uracil or to another base that is detectably dissimilar to cytosine in terms of hybridization properties;

contacting the treated genomic DNA, or the treated fragment thereof, with an amplification enzyme and at least two primers comprising, in each case a contiguous sequence at least 18 nucleotides in length that is complementary to, or hybridizes under moderately stringent or stringent conditions to a sequence selected from the group consisting of SEQ ID NOS;

133, 134, 261, 262, 189, 190, 317, 318, 101, 102, 229, 230, 962-965. and complements thereof, wherein the treated DNA or a fragment thereof is either amplified to produce one or more amplificates, or is not amplified;

determining, based on the presence or absence of, or on the quantity or on a property of said amplificate, the methylation state of at least one CpG dinucleotide sequence of at least one gene or sequence selected from the group consisting of PITX2, SEQ ID NO;

63, GPR7 and SEQ ID NO;

35, or an average, or a value reflecting an average methylation state of a plurality of CpG dinucleotide sequences of at least one gene or sequence selected from the group consisting of PITX2, SEQ ID NO;

63, GPR7 and SEQ ID NO;

35; and

determining from said methylation state the prognosis of said subject.

19. A treated nucleic acid derived from SEQ ID NOS:

961, 35, 63 and 19, wherein the treatment is suitable to convert at least one unmethylated cytosine base of the genomic DNA sequence to uracil or another base that is detectably dissimilar to cytosine in terms of hybridization.

21. The nucleic acid of any one of claims 19 and 20, wherein the contiguous base sequence comprises at least one CpG, TpG or CpA dinucleotide sequence.

22. The nucleic acid of any of claim 21, wherein the treatment comprises use of a reagent selected from the group consisting of bisulfite, hydrogen sulfite, disulfite, and combinations thereof.

20. A nucleic acid, comprising at least 16 contiguous nucleotides of a treated genomic DNA sequence selected from the group consisting of SEQ ID NOS:

133, 134, 261, 262, 189, 190, 317, 318, 101, 102, 229, 230, 962-965, and sequences complementary thereto, wherein said nucleic acid is not identical or complementary to SEQ ID NOS;

961, 35, 63 and 19, wherein the treatment is suitable to convert at least one unmethylated cytosine base of the genomic DNA sequence to uracil or another base that is detectably dissimilar to cytosine in terms of hybridization.

23. An oligomer, comprising a sequence of at least 9 contiguous nucleotides that is complementary to, or hybridizes under moderately stringent or stringent conditions to a treated genomic DNA sequence selected from the group consisting of SEQ ID NOS:

133, 134, 261, 262, 189, 190, 317, 318, 101, 102, 229, 230, 962-965, and sequences complementary thereto, wherein said nucleic acid is not identical or complementary to SEQ ID NOS;

961, 35, 63 and 19.

24. The oligomer of claim 23, comprising at least one CpG, CpA or TpG dinucleotide.

25. A kit for use in for use in providing a prognosis of a subject with a prostate cell proliferative disorder, comprising:

a means for detecting the polypeptides of a gene or genomic region selected from the group consisting of PITX2, HIST2H2BF, SEQ ID NO;

63, GPR7, FOXL2 and SEQ ID NO;

35.

26. The kit of claim 25, comprising:

(a) a means for detecting the polypeptides of a gene or genomic region selected from the group consisting of PITX2, HIST2H2BF, SEQ ID NO;

63, GPR7, FOXL2 and SEQ ID NO;

35;

(b) a container suitable for containing the said means and a biological sample of the patient comprising said polypeptides, wherein the means can form complexes with the polypeptides;

(c) a means to detect the complexes of (b); and

optionally (d) instructions for use and interpretation of the kit results.

27. A kit for use in providing a prognosis of a subject with a prostate cell proliferative disorder, comprising:

a means for measuring the level of mRNA transcription of a gene or genomic region selected from the group consisting of PITX2, HIST2H2BF, SEQ ID NO;

63, GPR7, FOXL2 and SEQ ID NO;

35.

28. The kit of claim 27, comprising:

(a) a means for measuring the level of mRNA transcription of a gene or genomic region selected from the group consisting of PITX2, SEQ ID NO;

63, GPR7 and SEQ ID NO;

35;

(b) a container suitable for containing the said means and a biological sample of the patient comprising mRNA of a gene or genomic region selected from the group consisting of PITX2, SEQ ID NO;

63, GPR7 and SEQ ID NO;

35, wherein the means are able to hybridize to the transcription products of said gene;

(c) a means for detecting the complexes of (b); and

optionally (d) instructions for use and interpretation of the kit results.

29. A kit comprising:

at least one of a bisulfite reagent; and

at least two nucleic acid molecules comprising, in each case a contiguous sequence at least 16 nucleotides that is complementary to, or hybridizes under moderately stringent or stringent conditions to a sequence selected from the group consisting of SEQ ID NOS;

133, 134, 261, 262, 189, 190, 317, 318, 101, 102, 229, 230, 962-965 and complements thereof.

30. A composition comprising the following:

a nucleic acid comprising a sequence at least 18 bases in length of a segment of the chemically pretreated genomic DNA according to one of the sequences taken from the group consisting of SEQ ID NOS;

133, 134, 261, 262, 189, 190, 317, 318, 101, 102, 229, 230, 962-965 and sequences complementary thereto, and

a buffer comprising at least one of the following substances;

magnesium chloride, dNTP, of taq polymerase, an oligomer, in particular an oligonucleotide or peptide nucleic acid (PNA)-oligomer, said oligomer comprising in each case at least one base sequence having a length of at least 9 contiguous nucleotides which is complementary to, or hybridizes under moderately stringent or stringent conditions to a pre-treated genomic DNA according to one of the SEQ ID NOS;

133, 134, 261, 262, 189, 190, 317, 318, 101, 102, 229, 230, 962-965 and sequences complementary thereto.

31. (canceled)